FDA in­spec­tion at In­dia phar­ma at cen­ter of the cis­platin short­age cites mul­ti­ple qual­i­ty is­sues

An FDA in­spec­tion of the In­tas Phar­ma­ceu­ti­cals man­u­fac­tur­ing fa­cil­i­ty in In­dia that pro­duces the can­cer drug cis­platin, now in short sup­ply, found in­stances of ma­nip­u­lat­ed doc­u­ments and clean­ing vi­o­la­tions.

The 483 in­spec­tion re­port was ob­tained by End­points News via a FOIA re­quest. It re­vealed a range of is­sues at the plant in Ahmed­abad, In­dia, in­clud­ing vi­su­al in­spec­tion records that had been al­tered to lessen the risk of a batch in­ves­ti­ga­tion and com­plaints of odors and smells that were nev­er checked out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER